Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – IgA Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
Phenylketonuria – Epidemiology – Epidemiology – Phenylketonuria – Mature Markets
Clarivate Epidemiology’s coverage of phenylketonuria comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Obesity – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity / Overweight (US)
As the prevalence of obesity rises, the demand for safe and effective treatments increases. Therapies mimicking GLP-1 and GIP peptides—hormones that regulate appetite and energy metabolism—have…
Forecast Landscape – Forecast Methodology and General Market Assumptions | 2025
In 2023, sales of branded biologics for oncology, immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $150 billion in the major pharmaceutical…
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology…
